Alveolar ridge and maxillary sinus augmentation using rhBMP-2: a systematic review

dc.contributorUniversidade Estadual Paulista (UNESP)
dc.creatorFreitas, Rubens Moreno de
dc.creatorSpin Neto, Rubens
dc.creatorMarcantonio Júnior, Elcio
dc.creatorPereira, Luís Antônio Violin Dias
dc.creatorWikesjö, Ulf Me
dc.creatorSusin, Cristiano
dc.date2015-08-06T16:12:39Z
dc.date2016-10-25T20:53:20Z
dc.date2015-08-06T16:12:39Z
dc.date2016-10-25T20:53:20Z
dc.date2015
dc.date.accessioned2017-04-06T08:35:05Z
dc.date.available2017-04-06T08:35:05Z
dc.identifierClinical Implant Dentistry and Related Research, v. 17, n. 1, p. e192–e201, 2013.
dc.identifier1523-0899
dc.identifierhttp://hdl.handle.net/11449/125629
dc.identifierhttp://acervodigital.unesp.br/handle/11449/125629
dc.identifierhttp://dx.doi.org/10.1111/cid.12156
dc.identifier6100859465871929
dc.identifier4943293233044062
dc.identifier4447288356115998
dc.identifierhttp://onlinelibrary.wiley.com/doi/10.1111/cid.12156/abstract
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/936225
dc.descriptionPurpose: The aim of this systematic review was to evaluate clinical and safety data for recombinant human bone morpho-genetic protein-2 (rhBMP-2) in an absorbable collagen sponge (ACS) carrier when used for alveolar ridge/maxillary sinusaugmentation in humans.Materials and Methods: Clinical studies/case ser ies published 1980 through June 2012 using rhBMP-2/ACS were searched.Studies meeting the following criteria were considered eligible for inclusion: >10 subjects at baseline and maxillary sinus oralveolar ridge augmentation not concomitant with implant placement.Results: Seven of 69 publications were eligible for review. rhBMP-2/ACS yielded clinically meaningful bone formationfor maxillary sinus augmentation that would allow placement of regular dental implants without consistent differencesbetween rhBMP-2 concentrations. Never theless, the statistical analysis showed that sinus augmentation following autog-enous bone graft was significantly greater (mean bone height: 1.6 mm, 95% CI: 0.5–2.7 mm) than for rhBMP-2/ACS(rhBMP-2 at 1.5 mg/mL). In extraction sockets, rhBMP-2/ACS maintained alveolar ridge height while enhancing alve olarridge width. Safety reports did not represent concerns for the proposed indications.Conclusions: rhBMP-2/ACS appears a promising alternative to autogenous bone grafts for alveolar ridge/maxillary sinusaugmentation; dose and carrier optimization may expand its efficacy, use, and clinical application.
dc.languageeng
dc.relationClinical Implant Dentistry and Related Research
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAlveolar ridge augmentation
dc.subjectBMP
dc.subjectBone morphogenetic proteins
dc.subjectBone regeneration
dc.subjectMaxillary sinusaugmentation
dc.titleAlveolar ridge and maxillary sinus augmentation using rhBMP-2: a systematic review
dc.typeOtro


Este ítem pertenece a la siguiente institución